Article
PLGA CMC Foundation: Mw, PDI, End Groups, and Approved Product Precedents
Teams working on PLGA nanoparticles routinely treat the polymer as a commodity excipient and its characterization as a formality, rather than as the rate-limiting quality attribute that determines…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
PLGA CMC Foundation: Mw, PDI, End Groups, and Approved Product Precedents
Teams working on PLGA nanoparticles routinely treat the polymer as a commodity excipient and its characterization as a formality, rather than as the rate-limiting quality attribute that determines…
Article
Macrophage and Dendritic Cell Therapy CMC — Innate Immune Cell-Based Drug Product Manufacturing and Control
Macrophages and dendritic cells are among the most functionally plastic cells in the immune system — a macrophage stimulated with M1-polarizing signals produces TNF-α, IL-12, and reactive oxygen…
Article
Regulatory T Cell (Treg) Therapy CMC — Isolation, Expansion, and the Potency Assay Challenge
Every cell therapy potency assay must measure the therapeutic activity of the drug product. For CAR-T therapies, that means cytotoxicity. For TIL therapies, it means antitumor killing. For…
Article
NK Cell Therapy CMC — Peripheral Blood, iPSC-Derived, and Cord Blood NK Platform Comparisons
Natural killer cell therapy offers the immunological logic for an off-the-shelf allogeneic product: NK cells kill HLA-mismatched targets through activating receptor engagement rather than antigen-specific TCR recognition, eliminating…
Article
Tumor-Infiltrating Lymphocyte (TIL) Therapy CMC — FDA and EMA Regulatory Framework for Ex Vivo Expansion
TIL therapy has achieved a regulatory milestone that few believed possible a decade ago — an FDA-approved autologous cell therapy with a manufacturing process that starts from a…
Article
Gamma-Delta T Cell Therapy CMC — MHC-Unrestricted Allogeneic Platform CMC Considerations
The argument for gamma-delta T cell therapy is compelling: γδ T cells kill tumors without HLA matching, can be manufactured from allogeneic donors at scale, and circumvent the…
Article
TCR-Engineered T Cell Therapy CMC — HLA-Restricted Recognition and the Module 3 Complexity Beyond CAR-T
TCR-T therapy teams that inherit the CAR-T CMC framework inherit the wrong starting point. CAR-T identity and potency assays are built around antigen recognition that is independent of…
Article
Post-Approval Cell Therapy Lifecycle — Managing Changes, Comparability, and Improvement Under a BLA
The most successful cell therapy programs treat BLA approval not as the end of CMC work, but as the beginning of the manufacturing lifecycle where every change requires…
Article
GMP Facilities for Cell Therapy — What CBER’s Facility Inspection Will Look For
A cell therapy BLA without a facility that passes inspection is a submission, not an approval. Understanding what CBER inspectors evaluate before you build or validate your facility…
Article
CBER and EMA CAT for Cell Therapy — Regulatory Differences That Demand a Dual-Region Strategy
A cell therapy CMC package built for CBER will satisfy many EMA requirements — and fail specific ones. Discovering which ones at pre-submission costs less than discovering them…
Article
From Cell Therapy IND to BLA — The CMC Development Roadmap That Prevents Phase 3 Crisis
The cell therapy programs that reach BLA submission on schedule are not the ones that moved fastest in Phase 1. They are the ones that invested in CMC…
Article
Cell Therapy Quality Overall Summary — Writing Module 2.3 for an Incompletely Characterized Drug
The QOS for a cell therapy product must summarize a drug that is, by definition, incompletely characterized. The way you handle that reality in Module 2.3 determines whether…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.